These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24247719)

  • 1. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
    Mok S; Koya RC; Tsui C; Xu J; Robert L; Wu L; Graeber T; West BL; Bollag G; Ribas A
    Cancer Res; 2014 Jan; 74(1):153-161. PubMed ID: 24247719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CSF-1R supports T-cell mediated melanoma therapy.
    Sluijter M; van der Sluis TC; van der Velden PA; Versluis M; West BL; van der Burg SH; van Hall T
    PLoS One; 2014; 9(8):e104230. PubMed ID: 25110953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
    Koya RC; Mok S; Otte N; Blacketor KJ; Comin-Anduix B; Tumeh PC; Minasyan A; Graham NA; Graeber TG; Chodon T; Ribas A
    Cancer Res; 2012 Aug; 72(16):3928-37. PubMed ID: 22693252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
    Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
    Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
    Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
    J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.
    Crompton JG; Sukumar M; Roychoudhuri R; Clever D; Gros A; Eil RL; Tran E; Hanada K; Yu Z; Palmer DC; Kerkar SP; Michalek RD; Upham T; Leonardi A; Acquavella N; Wang E; Marincola FM; Gattinoni L; Muranski P; Sundrud MS; Klebanoff CA; Rosenberg SA; Fearon DT; Restifo NP
    Cancer Res; 2015 Jan; 75(2):296-305. PubMed ID: 25432172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.
    Erkes DA; Rosenbaum SR; Field CO; Chervoneva I; Villanueva J; Aplin AE
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):372-377. PubMed ID: 31696640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
    Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
    Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts.
    Conlon KC; Anver MR; Longo DL; Ortaldo JR; Murphy WJ
    J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):317-23. PubMed ID: 8941871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.
    Priceman SJ; Sung JL; Shaposhnik Z; Burton JB; Torres-Collado AX; Moughon DL; Johnson M; Lusis AJ; Cohen DA; Iruela-Arispe ML; Wu L
    Blood; 2010 Feb; 115(7):1461-71. PubMed ID: 20008303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF
    Ngiow SF; Meeth KM; Stannard K; Barkauskas DS; Bollag G; Bosenberg M; Smyth MJ
    Oncoimmunology; 2016 Mar; 5(3):e1089381. PubMed ID: 27141346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.